Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes

Frontiers in Aging Neuroscience
Chin-Hsien LinMing-Jang Chiu

Abstract

Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples (n = 204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or frontotemporal dementia (FTD) with parkinsonism (FTD-P) or without parkinsonism. We measured plasma levels of α-synuclein, total tau, p-Tau181, and amyloid beta 42 (Aβ42) by immunomagnetic reduction-based immunoassay. Results: Plasma α-synuclein level was significantly increased in patients with PD and APS when compared with controls and FTD without parkinsonism (p < 0.01). Total tau and p-Tau181 were significantly increased in all disease groups compared to controls, especially in patients with FTD (p < 0.01). A multivariate and receiver operating characteristic curve analysis revealed that a cut-off value for Aβ42 multiplied by p-Tau181 for discriminating patients with FTD from patients with PD and APS was 92.66 (pg/ml)2, with an area under the c...Continue Reading

References

Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Jan 21, 2003·Archives of Neurology·Alexis ElbazWalter A Rocca
May 11, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·W Farid AbdoMarcel M Verbeek
Apr 5, 2005·Journal of Neuropathology and Experimental Neurology·Despina YancopoulouMaria Grazia Spillantini
Jun 2, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Murat EmreBruno Dubois
Nov 26, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzUNKNOWN Movement Disorder Society UPDRS Revision Task Force
Jun 5, 2010·Journal of Neurology, Neurosurgery, and Psychiatry·Kensaku KasugaTakeshi Ikeuchi
Jul 1, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Sigurd D SüssmuthHayrettin Tumani
Sep 14, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·M B AertsM M Verbeek
Apr 7, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Lucilla ParnettiOmar El-Agnaf
May 21, 2011·Brain : a Journal of Neurology·Yaroslau ComptaTamas Revesz
Jan 26, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Irene LitvanMurat Emre
Jan 30, 2013·Neurology·Melissa J ArmstrongWilliam J Weiner
Jan 15, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Leone ChareGlenda M Halliday
Apr 3, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Nadia MagdalinouHenrik Zetterberg
Jun 15, 2014·Journal of the Neurological Sciences·Hana Přikrylová VranováPetr Kaňovský
Oct 30, 2014·Molecular Neurodegeneration·Simon MoussaudPamela J McLean
Jan 16, 2015·Journal of Neurology, Neurosurgery, and Psychiatry·N K MagdalinouH Zetterberg
May 20, 2015·Neurobiology of Disease·Brice LaurensWassilios G Meissner
May 31, 2016·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Yolande A L PijnenburgCharlotte E Teunissen
Feb 10, 2017·Neurology·Oskar HanssonUNKNOWN Swedish BioFINDER study
Mar 23, 2017·Frontiers in Aging Neuroscience·Ming-Jang ChiuHerng-Er Horng
May 4, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Günter U HöglingerUNKNOWN Movement Disorder Society-endorsed PSP Study Group
May 27, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Manuel Delgado-AlvaradoMaría C Rodríguez-Oroz
May 28, 2017·Journal of Neurology, Neurosurgery, and Psychiatry·Chin-Hsien LinMing-Jang Chiu
Dec 29, 2017·Neurology·Julio C RojasUNKNOWN AL-108-231 Investigators

❮ Previous
Next ❯

Citations

Feb 5, 2019·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Anastasia BougeaElisabeth Kapaki
Apr 24, 2020·Nature Reviews. Neurology·Nicholas J AshtonDag Aarsland
Sep 25, 2020·International Journal of Molecular Sciences·Chin-Hsien LinMing-Jang Chiu
Nov 18, 2020·Clinical and Translational Science·Juhee KangJaerak Chang
Jun 27, 2019·Progress in Neurobiology·Thomas W RöslerGünter U Höglinger
Mar 8, 2021·European Journal of Nuclear Medicine and Molecular Imaging·N J AshtonO Hansson
Apr 16, 2021·Frontiers in Aging Neuroscience·Cheng-Hsuan LiChin-Hsien Lin
May 29, 2021·AJNR. American Journal of Neuroradiology·W-C LinK-H Chou

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
ELISA

Software Mentioned

Stata

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.